Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)

Rolapitant is a highly selective neurokinin-1 receptor antagonist, orally administered for a single dose of 180 mg before chemotherapy with granisetron D1, dexamethasone 8 mg BID on day 2–4. It has a unique pharmacological characteristic of a long plasma half-life (between 163 and 183 hours); this l...

Descripción completa

Detalles Bibliográficos
Autores principales: Rashad, Noha, Abdel-Rahman, Omar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5373840/
https://www.ncbi.nlm.nih.gov/pubmed/28392676
http://dx.doi.org/10.2147/DDDT.S108872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5373840/
https://www.ncbi.nlm.nih.gov/pubmed/28392676
http://dx.doi.org/10.2147/DDDT.S108872

Ejemplares similares